What is ACOG's current stock price?

ACOG (Alpha Cognition Inc. Common Stock) is currently trading at $5.85 with a market cap of $90.9M.

What sector is Alpha Cognition Inc. Common Stock in?

Alpha Cognition Inc. Common Stock (ACOG) operates in the Financial Services sector, specifically in the Financial - Conglomerates industry.

Is ACOG a good stock to buy?

Analysts have a Buy consensus on ACOG with a price target of $14.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ACOG Alpha Cognition Inc. Common Stock

Financial Services

$5.85+0.52%ClosedMarket Cap: $90.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.22

P/S

8.39

EV/EBITDA

-1.35

DCF Value

$8.97

FCF Yield

-33.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

86.4%

Operating Margin

-250.1%

Net Margin

-232.2%

ROE

-54.1%

ROA

-36.3%

ROIC

-42.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$3.5M	$-6.5M	$—
Q4 null	$2.8M	$-6.9M	$—
FY null	$10.2M	$-20.7M	$—
Q3 null	$2.8M	$-1.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$14.00

Target (Median)

$14.00

Target Range

$14.00 - $14.00

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-22

HC Wainwright & Co.Buy

2025-12-19

HC Wainwright & Co.Buy

2025-10-20

Trading Activity

Insider Trades

View All

Opaleye Management Inc.10 percent owner

BuyFri May 22

Opaleye Management Inc.10 percent owner

BuyFri May 22

Opaleye Management Inc.10 percent owner

BuyTue May 19

Opaleye Management Inc.10 percent owner

BuyTue May 19

D'Angelo Laurenofficer: Chief Operating Officer

BuyTue May 19

Company Info

Sector

Financial Services

Industry

Financial - Conglomerates

Country

Exchange

—

Beta

2.39

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Peers

SRL

XYF

YHNA